Tagomics published a Cell Reports Methods paper describing Active‑Seq, an enzymatic, azide‑click tagging method that enriches unmethylated DNA for base‑conversion‑free epigenomic profiling in cfDNA and low‑input samples — a workflow now commercialized as Activace for liquid biopsy biomarker discovery. The method identifies thousands of differential methylation regions in colorectal cancer cohorts and is optimized for one‑nanogram inputs. Meanwhile TruDiagnostic secured a $320,511 NIH SBIR grant to build a W‑Function Epigenomic Roadmap mapping DNA methylation dynamics for disease modeling in cardiovascular and metabolic disease. Both items advance epigenetic biomarker discovery and longitudinal methylation metrics critical to early detection and treatment monitoring.